Cytotoxic natural antibodies against human tumours: An option for anti-cancer immunotherapy?

Autoimmunity Reviews

Volumn 7, Issue 6, 2008, Pages 491-495

  Schwartz Albiez, Reinhard ^a   Laban, Simon ^a   Eichmüller, Stefan ^a   Kirschfink, Michael ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anti tumour cytotoxic natural antibodies; Complement; Membrane complement regulatory proteins (mCRP); Tumour surveillance; Tumour specific carbohydrate epitopes

Indexed keywords

BEVACIZUMAB; CARBOHYDRATE; CD20 ANTIGEN; CD59 ANTIGEN; CETUXIMAB; CYTOTOXIC ANTIBODY; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; IMMUNOGLOBULIN M ANTIBODY; MEMBRANE COFACTOR PROTEIN; MUCIN 1; RITUXIMAB; THOMSEN FRIEDENREICH ANTIGEN; TRASTUZUMAB; TUMOR ANTIGEN; VASCULOTROPIN;

APOPTOSIS; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; COLON CARCINOMA; COLORECTAL CARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; FLOW CYTOMETRY; GLIOMA; HUMAN; IMMUNOSURVEILLANCE; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; MELANOMA; NATURAL KILLER T CELL; OVARY CARCINOMA; PANCREAS CARCINOMA; PROSTATE CARCINOMA; REVIEW; TUMOR CELL DESTRUCTION;

ANTIBODIES, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; COMPLEMENT ACTIVATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; NEOPLASMS;

EID: 51749111190     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.03.012     Document Type: Review

References (23)

1. Kannagi R., Izawa M., Koike T., Miyazaki K., and Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95 (2004) 377-384
2. Kobata A., and Amano J. Altered glcosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 83 (2005) 429-439
3. Cao Y., Karsten U., Otto G., and Bannasch P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2,6-linked sialic acid in hepatocellular cracinomas and preneoplastic hepatocellular lesions. Virchows Arch 434 (1999) 503-509
4. Goletz S., Thiede B., Hanisch F.G., Schultz M., Peter-Katalinic J., Mueller S., et al. A sequencing strategy for the localization of O-glycosylation sites of MUC1 tandem repeats by PSD-MALDI mass spectrometry. Glycobiology 7 (1997) 881-896
5. Vollmers H.P., and Braendlein S. Natural igM: from parias to parvenus. Histol Histopathol 21 (2006) 1355-1366
6. Ollert M.W., David K., Schmit C., Hauenschild A., Bredehorst R Erttmann R., et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci U S A 93 (1996) 4498-4503
7. Ollert M.W., David K., Vollmert C., Juhl H., Erttmann R., Bredehorst R., and Vogel C.W. Mechanisms of in vivo antineuroblastoma activity of human natural IgM. Eur J Cancer 33 (1997) 1942-1948
8. Livingston P.O., Zhang S., and Lloyd K.O. Carobhydrate vaccines that induce antibodies against cancer. Cancer Immunol Immunother 45 (1997) 1-9
9. Modak S., and Cheung N.K. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Investig 25 (2007) 67-77
10. Imai M., Landen C., Ohta R., Cheung N.K.V., and Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 65 (2005) 10562-10568
11. Larkin J.M., Norsworthy P.J., A'Hern R.P., Eisen T.G., Gore M.E., and Porter C.D. Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma. Melanoma Res. 1 (2006) 157-163
12. Brändlein S., Lorenz J., Ruoff N., Hensel F., Beyer I., Muller J., et al. Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum Antib 11 (2002) 107-119
13. Varambally S., Ben-Dayan Y., Bayry J., Lacroix-Desmazes S., Horn M., Sorel M., et al. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol 16 (2004) 517-524
14. Lucas S.D., Karlsson-Parra A., Nilsson B., Grimelius L., Akerström G., Rastad J., et al. Tumour-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Human Pathol 27 (1996) 1329-1335
15. Idusogie E.E., Wong P.Y., Presta L.G., Gazzano-Santoro H., Totpal K., Ultsch M., et al. Engineered antibodies with increased activity to recruit complement. J Immunol 166 (2001) 2571-2575
16. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171 (2003) 1581-1587
17. Ullrich E., Bonnert M., Mignot G., Kroemer G., and Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differ 15 (2008) 21-28
18. Fishelson Z., Donin N., Zell S Schultz S., and Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumours. Mol Immunol 40 (2003) 109-123
19. Gorter A., and Meri S. Immune evasion of tumour cells using membrane-bound complement regulatory proteins. Immunol Today 20 (1999) 576-582
20. Kirschfink M., and Fishelson Z. Tumor cell resistance to complement-mediated lysis. In: Szebeni J. (Ed). The complement system: novel roles in health and disease (2004), Kluwer Academic Publ., Amsterdam 265-304
21. Jurianz K., Ziegler S., Donin N., Reiter Y., Fishelson Z., and Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 93 (2001) 848-854
22. Brasoveanu L.I., Altomonte M., Fonsatti E., et al. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 74 (1996) 33-42
23. Zell S., Geis N., Rutz R., Schultz S., Giese T., and Kirschfink M. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S_ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol 150 (2007) 576-586